Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesFRA:NB3 +1.27%94 Peter Lynch Fair Value is €138.70 as of Jul. 26, 2026, which is 100% below its 10-year median of 1.09. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €165.00 (Fairly Valued). The stock has 6 warning signs investors should review. Among 264 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 56.44% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Neurocrine Biosciences's PEG is 1. Neurocrine Biosciences's 5-Year TTM EBITDA Growth Rate is 25.
Neurocrine Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €5.55. Therefore, the Peter Lynch Fair Value for today is €138.70.
The historical rank and industry rank for Neurocrine Biosciences's Peter Lynch Fair Value or its related term are showing as below:
FRA:NB3'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.82 Med: 1.09 Max: 1.38
Current: 1.09
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Neurocrine Biosciences was 1.38. The lowest was 0.82. And the median was 1.09.
FRA:NB3's Price-to-Peter-Lynch-Fair-Value is ranked better than 56.44% of 264
companies
in the Drug Manufacturers industry
Industry Median: 1.225
vs FRA:NB3: 1.09
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Neurocrine Biosciences (FRA:NB3) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Neurocrine Biosciences's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
151.30
/
138.70
=
1.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Peter Lynch Fair Value Related Terms
Neurocrine Biosciences Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Peter Lynch Fair Value Chart
FRA:NB3 vs VTRS, ELAN, UTHR: Peter Lynch Fair Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Price-to-Peter-Lynch-Fair-Value falls into.
Neurocrine Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of €138.70 mean?
Neurocrine Biosciences (FRA:NB3) has a Peter Lynch Fair Value of €138.70 as of Jul. 26, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Neurocrine Biosciences and its competitors. This is 12625% above median its historical median of 1.09. Over the past decade, Neurocrine Biosciences' Peter Lynch Fair Value has ranged from 0.82 to 1.38. According to the industry distribution chart, Neurocrine Biosciences ranks #115 out of 264 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Neurocrine Biosciences' Peter Lynch Fair Value too high?
Neurocrine Biosciences' current Peter Lynch Fair Value of €138.70 is 12625% above median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 1.38. Based on the distribution chart, Neurocrine Biosciences ranks #115 out of 264 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Peter Lynch Fair Value compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #115 out of 264 companies for Peter Lynch Fair Value. This puts Neurocrine Biosciences in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.23. Historically, Neurocrine Biosciences' own Peter Lynch Fair Value has ranged from 0.82 to 1.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.23, based on 264 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Peter Lynch Fair Value is €138.70, which is 12625% above median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €165.00, compared to a current price of €151.30 — trading 8.3% below its estimated fair value. The current Peter Lynch Fair Value is €138.70, which is 12625% above median its 10-year median of 1.09. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Peter Lynch Fair Value is €138.70 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €151.30 is trading 8.3% below its estimated GF Value™ of €165.00.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for FRA:NB3:
Peter Lynch Fair Value: €138.70 (12625% above median its 10-year median of 1.09)
GF Value™: €165.00 vs. price of €151.30 (8.3% below fair value)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
